Table 2. Estimated Potency of Prescribed Blood Pressure–Lowering Drug Regimens by Group and Follow-up Visita.
| Estimated potency | Triple pill | Usual care | Mean difference (95% CI), mm Hg | P value | ||
|---|---|---|---|---|---|---|
| No. | Predicted SBP reduction, mean (SD), mm Hg | No. | Predicted SBP reduction, mean (SD), mm Hg | |||
| Randomization visit | ||||||
| Estimated mean regimen potency | 349 | 4.0 (5.2) | 351 | 4.3 (5.4) | −0.3 (−1.1 to 0.5) | .44 |
| Mean change in potency among those who received treatment intensificationb | 335 | 14.9 (6.3) | 252 | 9.6 (5.1) | 5.3 (4.4 to 6.2) | <.001 |
| Week 6 visit | ||||||
| Estimated mean regimen potency | 339 | 18.6 (3.8) | 347 | 11.2 (4.7) | 7.5 (6.8 to 8.1) | <.001 |
| Mean change in potency among those who received treatment intensificationb | 14 | 5.5 (5.8) | 70 | 5.2 (4.5) | 0.2 (−2.5 to 3.0) | .86 |
| Week 12 visit | ||||||
| Estimated mean regimen potency | 337 | 18.7 (4.2) | 345 | 12.4 (5.3) | 6.3 (5.6 to 7.1) | <.001 |
| Mean change in potency among those who received treatment intensificationb | 8 | 2.1 (4.6) | 63 | 4.1 (5.5) | −2.0 (−5.9 to 1.8) | .30 |
| Month 6 visit | ||||||
| Estimated mean regimen potency | 334 | 18.5 (4.8) | 341 | 13.1 (5.7) | 5.3 (4.5 to 6.1) | <.001 |
Abbreviation: SBP, systolic blood pressure.
a
Estimated treatment regimen potencies were calculated using methods from Law et al17 among patients who did not reach the blood pressure target and received intensification of blood pressure–lowering drug therapy. Data are provided on estimated regimen potency for patients who attended the visit and for those who received treatment intensification at the visit. Untreated patients were given an estimated potency of 0 mm Hg.
b
Change in regimen potency defined as the difference in predicted SBP reduction from the next visit and the current visit.